文献速递肿瘤 PET/CT甲状腺核医学

Al18F-NOTA-HER2-BCH与18F-FDG PET/CT在新诊断HER2低表达乳腺癌患者中的比较

Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-10

这项前瞻性研究于2021年11月至2024年3月纳入52例HER2低表达乳腺癌患者,均行Al18F-NOTA-HER2-BCH与18F-FDG PET/CT及配对肿瘤活检。Al18F-NOTA-HER2-BCH PET/CT显像可行且安全,未发生不良事件;52个HER2低表达活检病灶的中位SUVmax和TBR均低于18F-FDG PET/CT(6.6 vs. 10.5,P<.001;8.0 vs. 10.6,P=.009)。作者认为Al18F-NOTA-HER2-BCH摄取存在的个体间和个体内异质性提示其可作为无创评估疾病异质性和识别可能从HER2靶向治疗获益患者的潜在工具。

要点

  • 52例HER2低表达乳腺癌患者行Al18F-NOTA-HER2-BCH与18F-FDG PET/CT,未发生不良事件。
  • 52个活检病灶中位SUVmax 6.6 vs. 10.5(P<.001),中位TBR 8.0 vs. 10.6(P=.009),均为Al18F-NOTA-HER2-BCH低于18F-FDG。
  • Al18F-NOTA-HER2-BCH摄取存在个体间、个体内及不同器官系统间的异质性。

核心结论

  • Al18F-NOTA-HER2-BCH PET/CT对HER2低表达乳腺癌的显像可行且安全。
  • 观察到的Al18F-NOTA-HER2-BCH摄取个体内和个体间异质性提示其可作为无创评估疾病异质性和识别可能从HER2靶向治疗获益患者的潜在工具。

研究设计与样本

  • 前瞻性研究,开展时间为2021年11月至2024年3月。
  • 纳入52例经病理证实为HER2低表达(免疫组化评分1+或2+且原位杂交无HER2基因扩增)的乳腺癌患者,均为女性,平均年龄53.0±11.0岁。
  • 所有参与者均行Al18F-NOTA-HER2-BCH与18F-FDG PET/CT,并配有配对肿瘤活检。
  • Al18F-NOTA-HER2-BCH PET/CT于注射200 MBq Al18F-NOTA-HER2-BCH后3.5小时采集图像。
  • 采用最大标准化摄取值(SUVmax)和靶本比(TBR)定量示踪剂摄取。

主要发现

  • 未发生不良事件。
  • 52个HER2低表达活检病灶在Al18F-NOTA-HER2-BCH PET/CT上的中位SUVmax低于18F-FDG PET/CT(6.6 vs. 10.5,P<.001)。
  • 52个HER2低表达活检病灶在Al18F-NOTA-HER2-BCH PET/CT上的中位TBR低于18F-FDG PET/CT(8.0 vs. 10.6,P=.009)。
  • 共检出269个可疑病灶,18F-FDG PET/CT较Al18F-NOTA-HER2-BCH PET/CT显示更多可疑HER2低表达阳性病灶:乳腺(100% vs. 100%)、胸壁(100% vs. 100%)、淋巴结(83.9% vs. 77.7%)、骨(100% vs. 93.2%)、肝(66.7% vs. 52.4%)和肺(86.7% vs. 75.0%)。
  • Al18F-NOTA-HER2-BCH示踪剂摄取在参与者之间、同一参与者的不同转移灶之间、甚至不同器官系统内均存在明显的个体间和个体内差异。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the diagnostic performance and the whole-body heterogeneity of HER2 expression on Al18F-NOTA-HER2-BCH PET/CT in patients with HER2-low breast cancer. METHODS: In this prospective study conducted from November 2021 to March 2024, participants with HER2-low breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-low (immunohistochemistry score of 1 + or 2 + without HER2 gene amplification on in situ hybridization). PET/CT images were acquired 3.5 h after injection of 200 MBq of Al18F-NOTA-HER2-BCH. The maximum standardized uptake value (SUVmax) and target-to-background ratios (TBR) were used to quantify tracer uptake. RESULTS: Fifty-two participants with HER2-low breast cancer (mean age, 53.0 ± 11.0; 52 females) underwent Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT with paired tumor biopsies. No adverse events occurred. The median SUVmax and TBR of 52 HER2-low biopsy lesions on Al18F-NOTA-HER2-BCH PET/CT were lower than that on 18F-FDG PET/CT (6.6 vs. 10.5, P <.001; 8.0 vs. 10.6, P =.009). A total of 269 suspicious lesions were detected, 18F-FDG PET/CT depicted more suspected HER2-low positive lesions in breast (100% vs. 100%), chest wall (100% vs. 100%), lymph node (83.9% vs. 77.7%), bone (100% vs. 93.2%), liver (66.7% vs. 52.4%) and lung (86.7% vs. 75.0%) than Al18F-NOTA-HER2-BCH PET/CT. Additionally, clear interindividual and intraindividual differences on Al18F-NOTA-HER2-BCH tracer uptake was noted between participants, between different metastases in the same participants, even within different organ systems. CONCLUSION: The visualization of HER2-low breast cancer with Al18F-NOTA-HER2-BCH PET/CT was feasible and safe. The observed intra- and inter-individual heterogeneity in the uptake of Al18F-NOTA-HER2-BCH indicates its potential use as a noninvasive tool for assessing disease heterogeneity and identifying patients who may derive clinical benefit from HER2-targeted therapies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Guo X, Liang X, Li B, et al. Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40208315. doi:10.1007/s00259-025-07251-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。